Search Results

You are looking at 51 - 60 of 82 items for :

  • "fertility preservation" x
  • Refine by Access: All x
Clear All
Full access

Abstracts From the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care™

Intervention to Improve Decision Satisfaction and Decrease Regret in Women Considering Fertility Preservation Terri Lynn Woodard, MD; Laura Covarrubias, MSPH; Andrea Michele Bradford, PhD; and Leslie R. Schover, PhD From The University of Texas MD Anderson

Full access

Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Matthew Barth, Ana C. Xavier, Saro Armenian, Anthony N. Audino, Lindsay Blazin, David Bloom, Jong Chung, Kimberly Davies, Hilda Ding, James B. Ford, Paul J. Galardy, Rabi Hanna, Robert Hayashi, Cathy Lee-Miller, Andrea Judit Machnitz, Kelly W. Maloney, Lianna Marks, Paul L. Martin, David McCall, Martha Pacheco, Anne F. Reilly, Mikhail Roshal, Sophie Song, Joanna Weinstein, Sara Zarnegar-Lumley, Nicole McMillian, Ryan Schonfeld, and Hema Sundar

fertility preservation as clinically appropriate. Treatment Recommendations Primary Mediastinal Large B-Cell Lymphoma Initial Treatment Historically, pediatric patients with PMBL enrolled in prospective clinical trials of pediatric mature

Full access

The State of Cancer Care in America: Impact of State Policy on Access to High-Quality Cancer Care

Terrell Johnson, Lindsey A.M. Bandini, Kara Martin, Lee Jones, Jennifer Carlson, Ronald S. Walters, and Robert W. Carlson

-of-pocket costs for mature oocyte cryopreservation. 34 To resolve this oversight, Senator Lesser introduced Proposed Bill 5644 (PB 5644) in 2013, amending existing law to require fertility preservation in patients with cancer or anyone with a medical condition

Full access

State-of-the-Art Workup and Initial Management of Newly Diagnosed Molar Pregnancy and Postmolar Gestational Trophoblastic Neoplasia

Kevin M. Elias, Ross S. Berkowitz, and Neil S. Horowitz

(>39 or <19 years) have been identified as risk factors for failure of second curettage to avoid the need for chemotherapy. 59 , 60 Role of Hysterectomy Women with FIGO stage I nonmetastatic GTN who do not desire fertility preservation may be treated

Full access

Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Shrujal Baxi, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Elizabeth Kvale, Robin M. Lally, Terry S. Langbaum, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Deborah A. Freedman-Cass, and Nicole R. McMillian

Premenopausal cancer survivors who have received chemotherapy may experience transient or permanent menopause. 14 – 16 If appropriate and desired, referral for fertility preservation should be considered before chemotherapy, because studies report that 33% to

Full access

NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017

Arnel Pallera, Jessica K. Altman, Ellin Berman, Camille N. Abboud, Bhavana Bhatnagar, Peter Curtin, Daniel J. DeAngelo, Jason Gotlib, R. Tanner Hagelstrom, Gabriela Hobbs, Madan Jagasia, Hagop M. Kantarjian, Patricia Kropf, Leland Metheny, Joseph O. Moore, Evelena Ontiveros, Enkhtsetseg Purev, Albert Quiery, Vishnu V.B. Reddy, Michal G. Rose, Neil P. Shah, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Raoul Tibes, David T. Yang, Kristina Gregory, Hema Sundar, Michael Deininger, and Jerald P. Radich

mother and the potential risk to the fetus of continuing TKI therapy versus the risk of treatment interruption leading to the loss of optimal disease response must be carefully evaluated on an individual basis before initiation of TKI therapy. Fertility

Full access

Integration of Pediatric Hodgkin Lymphoma Treatment and Late Effects Guidelines: Seeing the Forest Beyond the Trees

Matthew J. Ehrhardt, Jamie E. Flerlage, Saro H. Armenian, Sharon M. Castellino, David C. Hodgson, and Melissa M. Hudson

health status and health-related quality of life into future decision-making algorithms, including the modifying impact of interventions (eg, the impact of fertility preservation on how a patient weighs the risk of infertility). Equally important will be

Full access

Hodgkin Lymphoma, Version 2.2015

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Nadia Khan, David G. Maloney, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Christina Tsien, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, and Hema Sundar

pregnancy test should be performed before women of childbearing age undergo treatment. 44 The guidelines recommend fertility preservation (semen cryopreservation in male patients, ovarian tissue or oocyte cryopreservation in female patients) before the

Full access

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Cecil M. Benitez, Karl Bernat, Philip J. Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. Kenkre, Nadia Khan, David G. Maloney, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Mitchell Smith, Jane N. Winter, Joachim Yahalom, Jennifer Burns, Ndiya Ogba, and Hema Sundar

fertility preservation (semen cryopreservation in male patients, ovarian tissue or oocyte cryo-preservation in female patients) before the initiation of chemotherapy with alkylating agents or pelvic RT. 41 , 42 Oophoropexy should be considered to preserve

Full access

Cervical Cancer

Benjamin E. Greer, Wui-Jin Koh, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, David K. Gaffney, Warner K. Huh, Daniel S. Kapp, John R. Lurain III, Lainie Martin, Mark A. Morgan, Robert J. Morgan Jr., David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr., Nelson Teng, and Fidel A. Valea

2B for node dissection only). However, if the patient is medically inoperable or if fertility is desired, patients with negative margins from cone biopsy could undergo observation. 62 , 63 For patients who desire fertility preservation